Contrasting Compugen (NASDAQ:CGEN) and OKYO Pharma (NASDAQ:OKYO)

Compugen (NASDAQ:CGEN) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Compugen and OKYO Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1	0	2	1	2.75
OKYO Pharma	1	1	3	0	2.40

Compugen currently has a consensus price target of $5.00, suggesting a potential upside of 75.44%. OKYO Pharma has a consensus price target of $6.33, suggesting a potential upside of 290.95%. Given OKYO Pharma’s higher possible upside, analysts clearly believe OKYO Pharma is more favorable than Compugen.

Volatility and Risk

Compugen has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500.

Earnings and Valuation

This table compares Compugen and OKYO Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76 million	3.70	$35.34 million	$0.37	7.70
OKYO Pharma	N/A	N/A	-$4.71 million	N/A	N/A

Compugen has higher revenue and earnings than OKYO Pharma.

Profitability

This table compares Compugen and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compugen	48.57%	55.68%	29.68%
OKYO Pharma	N/A	N/A	N/A

Institutional and Insider Ownership

12.2% of Compugen shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Compugen beats OKYO Pharma on 9 of the 12 factors compared between the two stocks.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.